Latest in NHS

Destiny Pharma receives US FDA QIDP designation for novel antibacterial product

Lead drug product in development for the prevention of post-surgical Staphyloccocal infections

Find out more
Destiny Pharma receives US FDA QIDP designation for novel antibacterial product

You need to be a subscriber to read this article.
Click here to find out more.
The path toward autonomous biopharma manufacturing

The path toward autonomous biopharma manufacturing

By connecting physical automation, robotics, AI and process knowledge into learning systems that accelerate development while preserving quality, safety and scientific rigour,...
See more
From Indonesia to the world: support Beta Pharmacon’s manufacturing excellence with GEA granulation technology

From Indonesia to the world: support Beta Pharmacon’s manufacturing excellence with GEA granulation technology

By integrating GEA granulation technology into its new facility, Beta Pharmacon has enhanced process control, reinforced its commitment to regulatory compliance, and secured GMP and USP qualifications to supply essential micronutrient supplements